We are live on ! Find out more
RLMD icon

Relmada Therapeutics
RLMD

93 hedge funds and large institutions have $66.5M invested in Relmada Therapeutics in 2024 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 21 increasing their positions, 26 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

111% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 9

51% more call options, than puts

Call options by funds: $907K | Put options by funds: $602K

17% more capital invested

Capital invested by funds: $56.7M → $66.5M (+$9.79M)

12% more funds holding

Funds holding: 83 → 93 (+10)

1.89% more ownership

Funds ownership: 45.55% → 47.44% (+1.9%)

19% less repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 26

Holders
93
Holders Change
+10
Holders Change %
+12.05%
% of All Funds
1.34%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
19
Increased
21
Reduced
26
Closed
9
Calls
$907K
Puts
$602K
Net Calls
+$305K
Net Calls Change
+$1.42M

Top Buyers

Rank Fund Capital Flow
1
VPC
Vestal Point Capital
New York
+$5.23M
2
Franklin Resources
Franklin Resources
California
+$3.04M
3
Jane Street
Jane Street
New York
+$786K
4
JP Morgan Chase
JP Morgan Chase
New York
+$757K
5
Millennium Management
Millennium Management
New York
+$687K

Top Sellers

Rank Fund Capital Flow
1
DTC
Deep Track Capital
Connecticut
-$3.88M
2
Citadel Advisors
Citadel Advisors
Florida
-$1.47M
3
Mirae Asset Global Investments
Mirae Asset Global Investments
South Korea
-$1.12M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$1.03M
5
OM
Opaleye Management
Massachusetts
-$569K
Name Holding Trade Value Shares
Change 		Change in
Stake
CG
76
Cutler Group
California
$41K -$1.45K -300 -3%
State Board of Administration of Florida Retirement System
77
State Board of Administration of Florida Retirement System
Florida
$34.1K +$72.8K +15,100 New
CFM
78
Catalyst Funds Management
Australia
$19.9K +$20.7K +4,290 New
HCP
79
Hexagon Capital Partners
Arkansas
$18.6K – – –
BBHC
80
Brown Brothers Harriman & Co
New York
$13.9K – – –
LC
81
Lindbrook Capital
California
$11.6K – – –
APW
82
Acima Private Wealth
Virginia
$8.57K – – –
RhumbLine Advisers
83
RhumbLine Advisers
Massachusetts
$5.46K – – –
ACM
84
ADAR1 Capital Management
Texas
$2.79K -$279K -58,000 -99%
ACA
85
American Capital Advisory
Idaho
$2.71K – – –
GI
86
GAMMA Investing
California
$2.65K – – –
Wells Fargo
87
Wells Fargo
California
$2.52K +$14 +3 +0.6%
TCM
88
Tang Capital Management
California
$1.78K +$1.84K +382 New
FFO
89
Fortitude Family Office
Arizona
$1.58K – – –
MPWT
90
MassMutual Private Wealth & Trust
Connecticut
$525 – – –
Osaic Holdings
91
Osaic Holdings
Arizona
$126 – – –
FRA
92
Front Row Advisors
California
$28 – – –
Macquarie Group
93
Macquarie Group
Australia
$4 +$4.13K +856 New
Mirae Asset Global Investments
94
Mirae Asset Global Investments
South Korea
– -$1.12M -270,396 Closed
Point72 Asset Management
95
Point72 Asset Management
Connecticut
– -$1.03M -250,000 Closed
XT
96
XTX Topco
Cayman Islands
– -$91.1K -22,009 Closed
Bank of New York Mellon
97
Bank of New York Mellon
New York
– -$46.4K -11,198 Closed
D.E. Shaw & Co
98
D.E. Shaw & Co
New York
– -$44.1K -10,649 Closed
Schroder Investment Management Group
99
Schroder Investment Management Group
United Kingdom
– -$41.4K -10,000 Closed
Royal Bank of Canada
100
Royal Bank of Canada
Ontario, Canada
– -$17K -4,151 Closed
1 2 3
4
5

RLMD Hedge Fund Activity: Q1 2024 in Review

93 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q1 2024, worth a combined $66.5M — up 17% from $56.7M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new RLMD positions and 9 closed out — a net gain of 10 holders — while 21 added to existing stakes and 26 trimmed.

The largest buyer was Vestal Point Capital, adding an estimated $5.23M. The largest seller was Deep Track Capital, cutting an estimated $3.88M.

  • 93 institutional investors held Relmada Therapeutics (RLMD) as of Q1 2024, up from 83 in Q4 2023.
  • Funds reported $66.5M of Relmada Therapeutics stock for Q1 2024, up 17% quarter-over-quarter.
  • 19 funds opened new Relmada Therapeutics positions in Q1 2024 and 9 closed out, a net change of +10 holders.
  • The largest Relmada Therapeutics buyer in Q1 2024 was Vestal Point Capital, an estimated $5.23M added.
  • The largest Relmada Therapeutics seller in Q1 2024 was Deep Track Capital, an estimated $3.88M sold.

Based on aggregated 13F filings for Q1 2024.